Todas las investigaciones
Activo, no reclutandoFASE3INTERVENCIONISTA

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Fabry disease is a rare inherited condition that can cause fatty substances to build up in the body. Over time, this build-up can make the walls of the heart thicker, which may lead to heart problems. This clinical trial looks at whether an experimental medicine called venglustat works well to reduce heart muscle thickening in people with Fabry disease. Adults aged 18 to 65 will be put into one of two groups by chance. One group will take venglustat tablets, while the other group will receive usual standard care treatments. The main part of the study lasts about 18 months, with hospital visits every three to six months for scans and health checks. If the trial goes well, participants may have the option to stay on venglustat for up to five years.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE3
Patrocinador
Sanofi
Objetivo de inscripción
104
Inicio
03 May 2022
Estimación de finalización
06 Dec 2027

¿De qué trata este estudio?

Fabry disease is a rare genetic condition where the body lacks an enzyme needed to clear out certain fatty substances. As these fats slowly build up inside cells, they can damage vital organs over time. One common and serious complication is an enlarged or thickened heart wall, known as left ventricular hypertrophy. When the heart muscle becomes too thick, it has to work much harder to pump blood around the body.

Currently, people with Fabry disease usually receive enzyme replacement therapy through regular intravenous drips, or take specific oral tablets if their genetic type allows. This study is testing a newer tablet medicine called venglustat. Instead of replacing the missing enzyme, venglustat aims to stop the fatty substances from being made in the first place, which may help shrink or stabilise the thickened heart muscle.

Researchers want to see if venglustat works better or just as well as existing standard treatments. Finding new ways to protect the heart could give people living with Fabry disease more treatment choices and potentially improve their long-term health and quality of life.

Puntos clave

  • Tests whether a new tablet, venglustat, helps reduce heart thickening in Fabry disease.
  • Open to adults aged 18 to 65 with a confirmed diagnosis of Fabry disease.
  • Compares the new tablet against standard NHS therapies over 18 months.
  • Clinic visits and heart scans occur every 3 to 6 months.
  • An optional long-term extension may allow participants to continue treatment for up to 5 years.

¿Quién puede ser elegible?

This trial is for men and women aged between 18 and 65 who have been diagnosed with Fabry disease and have noticeable thickening of their heart muscle. Participants can be people who are already on standard Fabry treatments or people who are not currently receiving treatment. Women must not be pregnant or breastfeeding, and all participants must agree to use effective contraception during the study.

You may not be able to take part if you have experienced serious heart problems in the past, such as a heart attack, stroke, heart failure, or heart surgery. People with significant scarring in the heart, severe kidney disease, active liver problems, or serious untreated mental health conditions will also be excluded to ensure their safety.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I am between 18 and 65 years old.
  2. I have a confirmed diagnosis of Fabry disease.
  3. My doctor has told me that my heart muscle is thickened (left ventricular hypertrophy).
  4. I have not had a stroke, heart attack, or major heart surgery.
  5. I do not have severe kidney or liver disease.
  6. I am not pregnant or breastfeeding, and I am willing to use reliable contraception.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join the trial, you will be placed into one of two groups by chance (randomised). You will either take venglustat tablets daily or receive one of the standard approved treatments for Fabry disease. The main treatment phase lasts around 18 months. During this time, you will visit the clinic every 3 to 6 months for regular health checks, blood tests, and heart MRI scans to measure your heart muscle. After finishing the initial 18 months, you may be invited to join an extension period where all participants receive venglustat, which can extend total participation up to roughly 5.3 years. You are free to stop participating at any time.

Riesgos y beneficios potenciales

Taking part may help reduce heart muscle thickening and offers regular, close monitoring by heart and rare disease specialists. However, there is no guarantee venglustat will improve your condition, and like all medicines, it may cause unforeseen side effects. You might also be placed in the standard care group rather than receiving the new drug. Participating requires regular hospital visits, scans, and blood tests. Taking part is completely voluntary, and you can leave the trial at any point without it affecting your standard NHS care.

Locations (54)

  • University of Alabama -The Kirklin Clinic- Site Number : 8400010
    Código postal verificado
    Birmingham, United States
  • University of California Los Angeles Medical Center- Site Number : 8400008
    Código postal verificado
    Los Angeles, United States
  • Emory University School of Medicine - Atlanta- Site Number : 8400009
    Código postal verificado
    Atlanta, Estados Unidos
  • Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005
    Código postal verificado
    Chicago, Estados Unidos
  • Maryam Banikazemi, MD- Site Number : 8400001
    Código postal verificado
    Hawthorne, United States
  • Renal Disease Research Institute- Site Number : 8400012
    Código postal verificado
    Dallas, United States
  • University of Utah Health Hospital- Site Number : 8400006
    Código postal verificado
    Salt Lake City, Estados Unidos
  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004
    Código postal verificado
    Fairfax, United States
  • Investigational Site Number : 0400001
    Código postal verificado
    Graz, Austria
  • Número de Sitio de Investigación: 1240003
    Código postal verificado
    Calgary, Canadá
  • Investigational Site Number : 1240006
    Código postal verificado
    Edmonton, Canadá
  • Investigational Site Number : 1240002
    Código postal verificado
    Vancouver, Canadá

Preguntas comunes

What is Fabry disease?

Fabry disease is a rare genetic condition where a missing enzyme causes fatty substances to build up inside blood vessels and organs, including the heart and kidneys.

How is venglustat taken?

Venglustat is an oral medicine taken by mouth as a tablet.

Can I choose which treatment I receive?

No. A computer randomly decides whether you receive venglustat or a standard treatment to ensure the test results are fair and unbiased.

Will I have to pay for the study treatment?

No. Clinical trial medicines and all study-related tests are provided free of charge, and travel expenses are usually covered.

What happens if I decide to leave the trial early?

You are free to leave at any time. Your medical team will safely transition you back to your regular NHS treatment plan.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.